Suraksha Diagnostic Ltd
Suraksha Diagnostic Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
1 of 3 strong
Not discussed on this call: fundraise, order book.
The short version
The company expects steady revenue growth, targeting around 15% annually, reflecting a conservative approach as they mature their operations. Revenue growth guidance is a conservative 15% in FY '27 but management aims for robust growth fueled by network expansion and new geographies. - EBITDA margins expected to increase; mature centers have achieved ~40.9% EBITDA margin, with overall target around 34% margin sustainable through FY '28 and beyond. - Genomic business, contributing margins around 15-20%, expected to witness strong continued growth and is a key growth pillar. - Test volume growth steady though moderate (~10-11% in Q1 FY '27), with potential to improve as genomic testing gains traction. - New centers currently breaking even within months, expected to improve overall profitability as they scale. - Company expanding aggressively toward 100 centers by FY '28, investing Rs.
From Suraksha Diagnostic Ltd's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- The company expects steady revenue growth, targeting around 15% annually, reflecting a conservative approach as they mature their operations.
- Test volume growth has been robust historically (~20% YoY), though recent quarters showed some moderation (~10-11%). Volume growth remains a key driver.
- Expansion plans include adding approximately 20 new labs in FY '27, with about 50% of new centers in newer geographies beyond core regions like Kolkata and West Bengal.
- Genomics business is seen as a significant growth pillar, with strong adoption and market education efforts underway; expected to contribute meaningfully over the next 3-4 years.
- Mature centers showed ~12.5% revenue growth quarter-on-quarter, expected to sustain this momentum.
- The company is on track to open 100 centers by FY '28, expanding its network and geographic footprint.
- Overall, sales, volumes, and revenues are expected to increase driven by network expansion, new test offerings, and deeper market penetration.
Profitability & Margins
See what Suraksha Diagnostic Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Genomic Capacity Investment: Rs. 22 crores invested over 3 years in genomic labs (Page 15).
- Future Genomics Capex: No substantial incremental CapEx expected in genomics for the next 2-3 years; existing CapEx is sufficient to leverage growth (Page 10).
- FY '27 Capex Outlook: Rs. 70-80 crores planned for the financial year for network expansion (Page 6).
- Center Expansion: Plan to open 6 spokes and 3 hubs in the current year, beyond centers already opened (Page 10).
- Strategic Exploration: Actively exploring inorganic acquisition opportunities if quality and price are favorable (Page 15).
- Target to open 100 centers by FY '28 on track with planned Capex (Page 6).
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Suraksha Diagnostic Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Suraksha Diagnostic Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹81 Cr, net profit ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Suraksha Diagnostic Ltd's management said in earlier quarters
Others in Healthcare Services this season
- Manipal Health Enterprises Ltd (Q1 FY27)
Volume-led growth with inpatient (IP) volumes up 39% and outpatient (OP) volumes up 26% year-on-year. Key concall takeaways from Manipal Health Enterprises…
- Fortis Healthcare Ltd (Q1 FY27)
IHH plans to increase its stake in Fortis to over 50% within 3-5 years, supporting long-term strategic growth. Key concall takeaways from Fortis Healthcare…
- Metropolis Healthcare Ltd (Q1 FY27)
East India currently 6%, with limited investment so far; future investments may increase contribution. Key concall takeaways from Metropolis Healthcare Ltd's…
- Apollo Hospitals Enterprise Ltd (Q1 FY27)
IP volume growth for established units guided at roughly 7% to 8%. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q1 FY27 earnings call — and how…
Frequently Asked Questions
What were Suraksha Diagnostic Ltd Q1 FY27 results?
The company expects steady revenue growth, targeting around 15% annually, reflecting a conservative approach as they mature their operations. Revenue growth guidance is a conservative 15% in FY '27 but management aims for robust growth fueled by network expansion and new geographies. - EBITDA margins expected to increase; mature centers have achieved ~40.9% EBITDA margin, with overall target around 34% margin sustainable through FY '28 and beyond. - Genomic business, contributing margins around 15-20%, expected to witness strong continued growth and is a key growth pillar. - Test volume growth steady though moderate (~10-11% in Q1 FY '27), with potential to improve as genomic testing gains traction. - New centers currently breaking even within months, expected to improve overall profitability as they scale. - Company expanding aggressively toward 100 centers by FY '28, investing Rs.
What is Suraksha Diagnostic Ltd share price analysis?
Suraksha Diagnostic Ltd currently shows a below-average growth signal. The stock trades at a P/E of 44.4 with a market cap of ₹1,588 Cr. Investors should review the full earnings analysis for detailed insights.
Is Suraksha Diagnostic Ltd planning capital expenditure?
Genomic Capacity Investment: Rs.
Keep Suraksha Diagnostic Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.